Full-Time

Legal Counsel II

Posted on 9/10/2024

Biorender

Biorender

201-500 employees

Online platform for creating scientific illustrations

No salary listed

Mid, Senior

Seattle, WA, USA

Remote-first with flexibility to work from anywhere, but Seattle is the primary location.

Category
Legal
Risk & Compliance
Intellectual Property (IP)
Legal & Compliance
Requirements
  • 5-10 years (Attorney) of in-house SaaS legal experience, particularly with IP, Commercial and Procurement support, Privacy, Product counseling.
  • Has strong personal success as a cross-functional team player.
  • US or Canada-based with global experience.
Responsibilities
  • Facilitate Go-To-Market (GTM) deal closings and renewals with prompt legal review and support, enabling the Director of Legal to focus on strategic company objectives, within the first 4 weeks.
  • Oversee legal operational matters, including administering our IronClad platform, collaborating with the Deal Desk lead, coordinating contract signatures, and managing vendor review requests within the first 2 months.
  • Serve as the go-to legal expert for intellectual property (IP), privacy, GTM, and product support, providing key insights and guidance across these critical areas.
  • Analyze, update, and optimize the legal playbook, specifically focusing on licensing, agreement negotiation, and other key policies, within the first 3 months.
  • Offer broad legal support across all company departments, including security, corporate, employment, and engineering, ensuring comprehensive legal coverage as needed.
  • Intellectual Property: Advise and provide best practices on IP matters, particularly with copyrights, brand protection and proactive measures for marketplace monitoring and enforcement of BioRender IP.
  • Commercial: Provide contract review support for new and renewal deals, including contract drafting and negotiation of NDA’s, SSA’s, DPA’s and review of order confirmations and quotes and any customer-provided paperwork.
  • Privacy: Identify and resolve gaps in our global data privacy compliance requirements.
  • Procurement: Provide contract support for procurement requests for new and existing vendors, including contract negotiation of NDA’s, MSA’s, DPA’s and review of vendor order forms and other vendor-provided paperwork.
  • Contracts: Maintain our contract management system (IronClad) and assist with contract intake and repository management, including obligation tracking. Coordinate signatures in Docusign for all documents requiring signatures.
  • Legal Support: Provide assistance to our Customer Experience team by addressing licensing inquiries and responding to ad hoc legal matters.
  • Corporate: Assist with maintaining our corporate organizational documents and assist with general corporate legal matters including equity administration and other duties, as needed.
  • Enablement: Provide enablement/training for new Sales, CS and CX members on legal processes. Maintain and build out our internal Legal resource pages in Notion.
  • Legal Operations: Identify and provide solutions for any inefficiencies or gaps with our legal processes and provide solutions.
  • Collaboration: Collaborate with cross-functional teams on various projects and initiatives.

BioRender provides an online platform for creating and sharing scientific illustrations tailored for the life sciences sector. Users can access thousands of pre-drawn icons and templates across more than 30 life sciences fields, allowing scientists, researchers, and educators to produce professional and visually appealing figures efficiently. The platform is designed to simplify the illustration process, making it easier for clients such as academic researchers, pharmaceutical companies, and educational institutions to create figures for research papers, presentations, and educational materials. BioRender operates on a subscription-based model, offering various plans that cater to different user needs, including enterprise solutions for larger organizations. The company's goal is to streamline the creation of scientific figures, saving users time and effort while enhancing the quality of scientific communication.

Company Size

201-500

Company Stage

Series A

Total Funding

$17.2M

Headquarters

Toronto, Canada

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased demand for visualization tools due to complex research topics like mutant proteins.
  • Growing interest in graphical abstracts enhances research visibility and engagement.
  • Rise of remote work models boosts demand for digital collaboration tools like BioRender.

What critics are saying

  • AI-driven design tools could reduce demand for BioRender's platform.
  • Increased competition from lower-cost visualization platforms may impact market share.
  • Rapid tech advancements may require costly updates to BioRender's platform.

What makes Biorender unique

  • BioRender offers a vast library of pre-drawn icons from over 30 life sciences fields.
  • The platform provides a user-friendly interface for creating professional scientific figures quickly.
  • BioRender's subscription model offers various plans, catering to diverse client needs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

5%

2 year growth

5%
PR Newswire
Nov 12th, 2024
Researchers Uncover New Role Of Mutant Proteins In Some Of The Deadliest Cancers

Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they found, helps to kick off a series of events involving the transport of specific nuclear proteins that lead to uncontrolled tumor growth, according to a study published Nov. 11, 2024, in Nature Cancer

PR Newswire
Apr 13th, 2023
Peel Therapeutics Reports Excessive Netosis Induction In Long Covid

Peer-reviewed study offers first description of ongoing NETosis induction in Long COVID; provides insights into pathogenesis and can serve as a surrogate marker for persistent pathology Research emphasizes need to explore neutrophil-targeted therapies in acute and chronic COVID-19SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis

Labiotech
Aug 24th, 2022
Study Findings Could Lead To New Anti-Cancer Drugs

Cancer cells surround themselves with a cloud of adenosine, thereby inhibiting the immune system (left). Ceritinib stops the formation of adenosine. ATP accumulates and activates immune cells (right). Figure: Laura Schäkel/University of Bonn – created with BioRender.com. German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system

WFMZ
Jun 15th, 2020
BioRender launched Graphical Abstract Contest on Jun 15th 20'.

Today BioRender, creator of the first web-based graphical tool for scientists to create publication and presentation-ready figures, announced its inaugural Graphical Abstract Contest, to give scientists a way to promote their research and win prize rewards.

INACTIVE